Patent and Exclusivity Expirations Report

Report generated for the week of 2025-09-15 by Unibest Digital Center. Current analysis scope only include the US FDA.

Visit Unibest Licensing serivce and explore FDF assets open for global licensing and/or technology transfer. 

Visit Unibest intermediates and APIs for global supply.

Summary of Expirations

This week, there are 2 drugs in the patent and exclusivity list. They are:

• Onzetra Xsail by Currax Pharmaceuticals, containing active ingredient Sumatriptan Succinate

• Pedmark by Fennec Pharmaceuticals, containing active ingredient Sodium Thiosulfate

Patents Expiring This Week

SUMATRIPTAN SUCCINATE - POWDER;NASAL - ONZETRA XSAIL

From CURRAX PHARMACEUTICALS LLC; to treat migraine headaches

EQ 11MG BASE

Approved in Jan 27, 2016, used as Reference Listed Drug and Reference Standard

There are 12 future patent(s) for this application. The earliest expires on 2026-02-23, and the latest expires on 2034-10-20.

Patent No	Patent Use Code	Patent Use Definition	Patent Expiration Date	Patent Title
9108015			2025-09-15	Nasal delivery devices
8590530	U-1809	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY	2025-09-15	Nasal delivery devices

Exclusivities Expiring This Week

SODIUM THIOSULFATE - SOLUTION;INTRAVENOUS - PEDMARK

From FENNEC PHARMACEUTICALS INC; to decrease the risk of hearing loss in children 1 month of age and older who are receiving cisplatin for solid tumors (cancer) that have not spread to other parts of the body.

12.5GM/100ML (125MG/ML)

Approved in Sep 20, 2022, used as Reference Listed Drug and Reference Standard

There are 1 future exclusivity(ies) for this drug product. The earliest expires on 2029-09-20, and the latest expires on 2029-09-20.

Exclusivity Date	Exclusivity Use Definition
2025-09-20	NEW PRODUCT